ACM
VNDA icon

Aviance Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Aviance Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-15,457
Closed -$221K – 316
2014
Q4 		$221K Sell
15,457
-2,594
-14% -$30.7K 0.01% 292
2014
Q3 		$187K Sell
18,051
-4,711
-21% -$61.7K 0.01% 283
2014
Q2 		$368K Sell
22,762
-1,053
-4% -$14K 0.02% 246
2014
Q1 		$387K Buy
+23,815
New +$339K 0.02% 227

Other funds holding VNDA

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Aviance Capital Management's VNDA Position: Q1 2015 in Review

Aviance Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 15,457 shares — an estimated $221K sold.

Aviance Capital Management first reported a position in VNDA in Q1 2014 and held it in 4 quarters. The position peaked at $387K in Q1 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

  • Aviance Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Aviance Capital Management sold 15,457 Vanda Pharmaceuticals shares in Q1 2015, an estimated $221K.
  • Aviance Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2014 and held it in 4 quarters.
  • Aviance Capital Management's Vanda Pharmaceuticals position peaked at $387K in Q1 2014.
  • 110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on Aviance Capital Management's 13F filing for Q1 2015, filed 14 May 2015.